Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 79
Current trends for investment in HIV prevention R&D by technology
Overall numbers by year. For more detailed information, visit www.hivresourcetracking.org.
Prevention Option:
HIV Testing for Advocates
This slide deck provides and overview of HIV testing—types of test, WHO guidelines, current issues in testing, looking ahead, resources and more.
Prevention Option:
Undetectable = Untransmittable Resources
This website from the Prevention Access Campaign is filled with links to the latest information on Undetectable = Untransmittable as well as other pertinent documents and resources.
Prevention Option:
AVAC’s “3D” View of the World: 2019 and beyond
This infographic lays out AVAC’s top-line recommendations from AVAC Report 2019: Now What? The recommendations fall into three categories: deliver — prevention programs whose impact is well-measured and -defined; demonstrate — next-generation...
Prevention Option:
UNAIDS Fast-Track Targets: The plan and the progress
The most widely-known UNAIDS Fast-Track goals were the 90-90-90 targets focused on diagnosing people with HIV, linking them to ART and supporting them to achieve virologic suppression. But these were only part of what the UNAIDS modelers said was...
Prevention Option:
Declines but Not a Decisive Effect of the Intervention
UNAIDS’ Fast-Track Goals for ending the epidemic focused on testing 90 percent of people living with HIV, linking 90 percent of those people to ART, and supporting 90 percent of those individuals to reach virologic suppression. This busy...
Prevention Option:
Visualizing Multisectoral Prevention: The DREAMS program theory of change
This is PEPFAR’s own visualization of how its AGYW programs can effect change. It’s notable for the definition of a care package that touches on the individual and her community, and for the way it defines a range of outcomes. There isn’t...
Prevention Option:
Universal Test and Treat (UTT) Trial Results
As this table shows, the two trials that offered community-wide testing in both arms (SEARCH, TasP) did not find a difference in incidence between the arms. One explanation may be that the expanded access to testing and linkage in both arms had an...
Prevention Option:
One Timeline, Two Stories, One Message: Putting trials and targets together
One problem with HIV prevention agendas is that they either live in an eternal present or in a far-off future. It’s “work with what we’ve got, which is condoms and VMMC and a little bit of PrEP”, or it’s “nothing can change without an...
Prevention Option:
Investment in HIV Prevention R&D by Top Philanthropic Funders in 2017
Global philanthropic funding increased by 4.1 percent from 2016 levels and amounted to US$164 million, or 14.6 percent of overall funding. The Bill and Melinda Gates Foundation (BMGF) remained the largest funder and increased its contribution by 6.6...
Prevention Option:
showing 1-10 of 79